AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Update

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 3,204,092 shares, a decline of 54.3% from the May 31st total of 7,013,343 shares. Approximately 22.0% of the company’s shares are sold short. Based on an average trading volume of 51,555,532 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their price target on AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, AIM ImmunoTech has an average rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Trading Down 4.1%

Shares of AIM ImmunoTech stock traded down $0.01 during trading on Tuesday, hitting $0.28. 1,095,995 shares of the company were exchanged, compared to its average volume of 11,463,011. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.01 and a quick ratio of 1.01. The firm’s fifty day moving average price is $0.43 and its 200 day moving average price is $0.81. AIM ImmunoTech has a 1-year low of $0.21 and a 1-year high of $20.35.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter. Sell-side analysts anticipate that AIM ImmunoTech will post -0.63 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AIM ImmunoTech

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Corient Private Wealth LLC bought a new stake in shares of AIM ImmunoTech in the 2nd quarter valued at $87,000. Sabby Management LLC bought a new position in AIM ImmunoTech during the third quarter worth about $79,000. Finally, DRW Securities LLC lifted its holdings in AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares in the last quarter. 12.02% of the stock is owned by institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.